A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

You may be eligible if

• Histologically confirmed diagnosis of a solid tumor
• Malignancy with either a KRAS G12C or KRAS G12S mutation
• Unresectable or metastatic disease
• No available treatment with curative intent
• Adequate organ function
• Measurable disease per RECIST v1.1
• Must be able to swallow with no GI condition that prevents absorption